Rexahn’s portfolio consists of unique compounds to treat a wide variety of conditions in cancer and CNS. Our diversified pipeline promises to improve the standards of care for multiple diseases. Among our first-in-class drug candidates is Serdaxin®, a well characterized chemical entity tested for multiple CNS indications. Data from a Phase IIa study shows that it improves symptoms of major depressive disorder (MDD). Serdaxin also promotes survival of neuronal cells in animal studies, suggesting it may provide an innovative approach for the treatment of other brain conditions, such as Parkinson’s and Alzheimer’s diseases.
Zoraxel™ is another potential game-changing drug. Unlike other erectile dysfunction (ED) drugs targeting peripheral blood flow, Zoraxel boosts sexual functions by directly modulating specific brain activities. This mechanism gives Zoraxel a superior safety profile and promises increased patient satisfaction over standard medications such as Viagra®. The Phase IIa clinical trial of Zoraxel has been completed with positive results and the Phase IIb trial is underway and will continue through 2010-11.
In the oncology sector, Archexin® is a pioneer compound with FDA orphan designation in the treatment of refractory cancers in various organs including the pancreas and ovaries. In contrast to conventional chemotherapy, Archexin specifically blocks the production of Akt-1, a molecule that plays a central role in the uncontrolled growth of tumor mass. Therefore, Archexin may be able to replace the current standard cancer therapy with improved efficacy and tolerability. Archexin is in Phase II clinical trials for the treatment of pancreatic cancer.
